- Home
- KXIN vs SLRX Comparison
KXIN vs SLRX Comparison
Compare KXIN & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KXIN | SLRX |
|---|---|---|
| Founded | 2015 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 3.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KXIN | SLRX |
|---|---|---|
| Price | $6.61 | $0.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 339.2K | ★ 341.4K |
| Earning Date | 11-26-2019 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $95,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.94 | $0.51 |
| 52 Week High | $55.50 | $108.00 |
Technical Indicators
Market Signals| Indicator | KXIN | SLRX |
|---|---|---|
| Relative Strength Index (RSI) | 70.18 | 34.09 |
| Support Level | $4.87 | $0.51 |
| Resistance Level | $6.20 | $0.68 |
| Average True Range (ATR) | 0.80 | 0.06 |
| MACD | 0.16 | 0.06 |
| Stochastic Oscillator | 90.25 | 40.81 |
Price Performance
Historical ComparisonAbout KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.